Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 Months Following Initiation of Erenumab: A US Retrospective Real-World Analysis.

Autor: Urman R; Amgen Inc., One Amgen Centre Drive, Thousand Oaks, CA, 91320, USA. rurman@amgen.com., Princic N; Merative, Ann Arbor, MI, USA., Vuvu F; Amgen Inc., One Amgen Centre Drive, Thousand Oaks, CA, 91320, USA., Patel LB; Amgen Inc., One Amgen Centre Drive, Thousand Oaks, CA, 91320, USA., Oh S; Amgen Inc., One Amgen Centre Drive, Thousand Oaks, CA, 91320, USA., Chandler D; Amgen Inc., One Amgen Centre Drive, Thousand Oaks, CA, 91320, USA., Hindiyeh N; Independent Consultant, San Diego, CA, USA., Bensink ME; Benofit Consulting, Brisbane, QLD, Australia.
Jazyk: angličtina
Zdroj: Pain and therapy [Pain Ther] 2024 Oct; Vol. 13 (5), pp. 1299-1313. Date of Electronic Publication: 2024 Aug 23.
DOI: 10.1007/s40122-024-00644-z
Abstrakt: Introduction: Erenumab-aooe is approved for the preventive treatment of migraine in adults. Recent publications have evaluated migraine medication use during the 6 months after starting erenumab, but longer-term follow-up data are limited. The objective of this study was to describe 12-month medication use and changes in healthcare resource utilization (HRU) and associated direct costs among patients initiating erenumab.
Methods: We identified adult patients with an erenumab claim in the Merative MarketScan Commercial and Medicare Databases from May 2018 through September 2019. Eligible patients had ≥ 12 months of continuous medical and pharmacy coverage before (pre-index period) and after (post-index period) the index date (first erenumab claim) in addition to pre-index evidence of migraine. Patients were stratified by post-index-period adherence to erenumab, defined as ≥ 80% of days covered (adherent) or < 80% of days covered (non-adherent). Outcomes were measured pre- and post-index, and differences between these periods were described.
Results: Among 7528 eligible patients, the mean (standard deviation) age was 45.1 (11.4) years and 85.4% were female; 38.5% of patients were adherent to erenumab. Most patients used acute or traditional migraine-preventive medications pre-index, with reductions in use observed post-index (acute medication was used by 95.6% of patients pre-index, compared to 92.3% post-index; traditional preventive medication was used by 89.6% of patients pre-index, compared to 81.9% post-index). Reductions were observed for HRU of emergency room visits (- 3.8%) and brain- and other head-imaging studies (- 7.5%). Overall costs associated with acute and traditional preventive medications were reduced (- $764), but costs for HRU increased slightly ($76). When stratifying by adherence and combining costs for acute and traditional preventive medications and HRU, adherent patients had cost decreases (- $1947), while non-adherent patients had cost increases ($101).
Conclusion: Most patients initiating erenumab had prior use of acute and traditional migraine-preventive therapies. The reduction in acute and traditional migraine-preventive medication use and HRU over the 12-month follow-up supports the long-term clinical benefits of erenumab in the real-world setting.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje